136816-99-4

Basic information

• Product Name: 1H-indol-2-yl[4-(3-nitropyridin-2-yl)piperazin-1-yl]methanone
• Synonyms: Piperazine, 1-(1H-indol-2-ylcarbonyl)-4-(3-nitro-2-pyridinyl)-
• CAS NO: 136816-99-4
• Molecular Formula: C₁₈H₁₇N₅O₃
• Molecular Weight: 351.3593
• Mol File: 136816-99-4.mol
• Article Data: 4

Chemical Properties

• Boiling Point: 632.7°C at 760 mmHg
• Flash Point: 336.4°C
• Density: 1.42g/cm³
• Vapor Pressure: 6.5E-16mmHg at 25°C
• Refractive Index: 1.709
• CAS DataBase Reference: 1H-indol-2-yl[4-(3-nitropyridin-2-yl)piperazin-1-yl]methanone(CAS DataBase Reference)
• NIST Chemistry Reference: 1H-indol-2-yl[4-(3-nitropyridin-2-yl)piperazin-1-yl]methanone(136816-99-4)
• EPA Substance Registry System: 1H-indol-2-yl[4-(3-nitropyridin-2-yl)piperazin-1-yl]methanone(136816-99-4)

Safety Data

• Hazardous Substances Data: 136816-99-4(Hazardous Substances Data)

Usage

Molecular structure

1H-indol-2-yl[4-(3-nitropyridin-2-yl)piperazin-1-yl]methanone consists of an indole ring, a piperazine ring, and a nitropyridinyl group.

Enzyme inhibition

It is a highly specific and potent inhibitor of the enzyme Monoamine oxidase A.

Pharmaceutical applications

The compound has potential applications in the treatment of depression, anxiety, and other mood disorders.

Neurotransmitter regulation

It can regulate neurotransmitters such as serotonin and dopamine in the brain.

Cancer therapy potential

The compound has been studied for its ability to inhibit the growth of cancer cells.

Diverse applications

1H-indol-2-yl[4-(3-nitropyridin-2-yl)piperazin-1-yl]methanone has a wide range of potential applications in the fields of medicine and research.

Upstream product

• 5470-18-8 2-Chloro-3-nitropyridine 
• 136818-95-6 (1H-indol-2-yl)(piperazin-1-yl)methanone 
• 58881-45-1 Indole-2-carbonyl chloride 
• 87394-48-7 1-(3-nitro-2-pyridinyl)piperazine 
• 1477-50-5 Indole-2-carboxylic acid 

Downstream Products

• 136818-09-2 1-(indolyl-2-carbonyl)-4-(3-amino-2-pyridyl)piperazine 
• 153473-53-1 1-(indolyl-2-carbonyl)-4-(3-acetamido-2-pyridyl)piperazine 
• 136816-90-5 1-(indolyl-2-carbonyl)-4-<3-<(cyclopropylmethyl)amino>-2-pyridyl>piperazine 
• 153473-56-4 1-(indolyl-2-carbonyl)-4-<3-(benzylamino)-2-pyridyl>piperazine 

Relevant articles and documents

In vitro antibacterial and antifungal activity and computational evaluation of novel indole derivatives containing 4-substituted piperazine moieties

Background: Lack of specificity and occurence of resistance to current antibacterial and antifungal agents are major shortcomings for the treatment of microbial diseases. Finding novel antimicrobial agents is therefore highly needed to develop more potent drugs. Within this framework, several indole derivatives were designed and reported in the literature. Methods: In vitro antibacterial and antifungal activities of previously synthesized novel indole compounds containing 4-substituted piperazine moieties were tested against Staphylococcus aureus (ATCC 25923), Methicilline resistant Staphylococcus aureus (MRSA, ATCC 43300), Escherichia coli (ATCC 25922), Bacillus subtilis (ATCC 6633) and Candida albicans (ATTC 10231). Sultamicillin T, ampicillin, ciprofloxacin and fluconazole were used as positive controls. Molecular docking was used to study the interaction of active compounds with their receptor. Results: Fifteen compounds were synthesized and their antibacterial activities were similar to that of the reference drugs used as controls. Compounds 4 and 15 were more active (MIC 25 μg/ml) than ampicillin (MIC 50 μg/ml) against MRSA, while they showed the same activity as sultamicillin T (MIC 25 μg/ml). All compounds showed lower activity than ciprofloxacin (MIC 25 μg/ml) against the tested microorganisms. However, none of the compounds showed remarkable antifungal activity against C. albicans. Conclusion: Compound 6 showed the best interaction with the amino acid residues of the targeted cofactor NAD+.

Anti-aids piperazines

The present invention includes diaromatic substituted heterocyclic compounds (III) STR1 which are useful in treating individuals infected with the HIV virus. The invention includes certain previously generically disclosed anti-AIDS piperazinyl compounds (V) and a method of treating HIV infected individuals with the indoles of formula (V) and the anti-AIDS amines (X).